Personalized cell therapy takes on Lung-Lining tumors

This early-phase trial is testing a new immunotherapy called Fast TILs for people with metastatic cancer or mesothelioma that has spread to the pleura (the lining around the lungs). The treatment uses the patient's own immune cells collected from their pleural fluid, which are multiplied in a lab and then delivered back into the chest through a catheter, along with a low dose of Interleukin-2. The main goals are to see if this approach is safe and if the personalized cell product can be made reliably. Only 10 participants will be enrolled, and the active treatment lasts about three weeks, with follow-up over five years.